IRIS UniCatt

Scaldaferri, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.256
AS - Asia 9.588
EU - Europa 8.610
SA - Sud America 2.070
AF - Africa 271
OC - Oceania 47
Continente sconosciuto - Info sul continente non disponibili 20
Totale 32.862
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.783
SG - Singapore 4.279
CN - Cina 2.131
IT - Italia 1.869
DE - Germania 1.801
BR - Brasile 1.649
SE - Svezia 1.384
VN - Vietnam 887
FR - Francia 879
GB - Regno Unito 431
PL - Polonia 372
IE - Irlanda 360
UA - Ucraina 355
IN - India 343
FI - Finlandia 339
ID - Indonesia 287
JP - Giappone 270
CA - Canada 253
HK - Hong Kong 244
BD - Bangladesh 227
TR - Turchia 186
RU - Federazione Russa 179
AR - Argentina 157
MX - Messico 133
NL - Olanda 126
KR - Corea 124
IR - Iran 114
ES - Italia 105
IQ - Iraq 103
ZA - Sudafrica 90
BE - Belgio 64
EC - Ecuador 64
AT - Austria 58
PK - Pakistan 45
CO - Colombia 42
CZ - Repubblica Ceca 39
VE - Venezuela 39
SA - Arabia Saudita 38
UZ - Uzbekistan 37
AU - Australia 36
PE - Perù 36
CL - Cile 32
MA - Marocco 32
EG - Egitto 31
PH - Filippine 31
CH - Svizzera 30
LT - Lituania 28
CI - Costa d'Avorio 26
JO - Giordania 25
TN - Tunisia 25
RO - Romania 23
NP - Nepal 22
BG - Bulgaria 20
IL - Israele 20
JM - Giamaica 19
PY - Paraguay 19
TW - Taiwan 18
AZ - Azerbaigian 17
PT - Portogallo 17
EU - Europa 16
MY - Malesia 16
UY - Uruguay 16
TH - Thailandia 15
AE - Emirati Arabi Uniti 14
KE - Kenya 13
KZ - Kazakistan 13
AL - Albania 12
HR - Croazia 12
HU - Ungheria 12
CR - Costa Rica 11
DZ - Algeria 11
OM - Oman 11
BO - Bolivia 10
BY - Bielorussia 10
HN - Honduras 10
BA - Bosnia-Erzegovina 9
GR - Grecia 9
NO - Norvegia 9
DO - Repubblica Dominicana 8
ET - Etiopia 8
NZ - Nuova Zelanda 8
SI - Slovenia 8
CY - Cipro 7
DK - Danimarca 7
NG - Nigeria 7
PS - Palestinian Territory 7
TT - Trinidad e Tobago 7
KG - Kirghizistan 6
LB - Libano 6
RS - Serbia 6
EE - Estonia 5
KW - Kuwait 5
LV - Lettonia 5
MK - Macedonia 5
NI - Nicaragua 5
PA - Panama 5
PR - Porto Rico 5
SK - Slovacchia (Repubblica Slovacca) 5
SY - Repubblica araba siriana 5
AM - Armenia 4
Totale 32.756
Salva come PNG Salva come JPEG
Città #
Singapore 2.466
Chandler 1.397
Ashburn 1.318
San Jose 1.284
Beijing 472
New York 405
Los Angeles 391
Rome 353
Dublin 350
Warsaw 305
Ho Chi Minh City 289
Jacksonville 243
Lauterbourg 241
Jakarta 240
Tokyo 239
Hefei 233
Hanoi 231
Milan 205
Frankfurt am Main 204
San Mateo 202
Hong Kong 191
The Dalles 188
Munich 186
São Paulo 180
Dallas 179
Boston 172
Ann Arbor 170
Wilmington 165
Nanjing 147
Council Bluffs 142
Helsinki 136
Cattolica 125
Marseille 118
Houston 115
Princeton 115
Chicago 112
Buffalo 104
Fairfield 102
Santa Clara 96
Seattle 95
Seoul 95
Boardman 91
Dearborn 90
Moscow 88
Woodbridge 88
Redwood City 85
London 77
Brooklyn 74
Nürnberg 71
Orem 71
Turku 71
Izmir 70
Montreal 70
North Bergen 69
Kent 67
Nuremberg 66
St Louis 65
Stockholm 65
Toronto 65
Hangzhou 63
Lawrence 62
Paris 62
Bremen 59
Denver 58
Phoenix 57
Atlanta 56
Shanghai 54
Brussels 52
Lappeenranta 52
Rio de Janeiro 51
Baghdad 49
Pune 48
Chennai 46
Nanchang 46
Belo Horizonte 44
Poplar 44
Da Nang 43
Johannesburg 43
Redmond 42
Tianjin 42
Amsterdam 40
San Francisco 40
Hyderabad 37
Augusta 36
Düsseldorf 36
Guangzhou 36
Hebei 36
Shenyang 36
Mexico City 35
Naples 35
Detroit 34
Lancaster 34
Haiphong 33
Mountain View 33
Cambridge 32
Vienna 32
Charlotte 31
Memphis 31
Washington 31
Mumbai 30
Totale 17.105
Salva come PNG Salva come JPEG
Nome #
The interpaly between immune system and microbiota in gynecological diseases : a narrative review. 737
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 374
Food Components and Dietary Habits: Keys for a Healthy Gut Microbiota Composition. 352
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis 333
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 329
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 282
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 234
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin 232
Complex Muco-cutaneous Manifestations of CARMIL2-associated Combined Immunodeficiency: A Novel Presentation of Dysfunctional Epithelial Barriers 220
The role of diet on gut microbiota composition 218
The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease 210
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 210
Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a 'patchy cutaneous' immune suppression? 209
Management of acute dyarrhea: current and future trends 208
Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases 207
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders? 200
The gut barrier: new acquisitions and therapeutic approaches 199
null 198
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 191
13C-octanoic acid breath test to study gastric emptying time 186
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises From a First Meta-Analysis 183
Bacterial flora as a cause or treatment of chronic diarrhea 180
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 178
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? 176
RECURRENT PREGNANCY LOSS IS ASSSOCIATED TO LEAKY GUT: A NOVEL PATHOGENIC MODEL OF ENDOMETRIUM INFLAMMATION ? 176
Intercellular adhesion molecule 1 gene polymorphisms in inflammatory bowel disease 175
Proinflammatory and Cancer-Promoting Pathobiont Fusobacterium nucleatum Directly Targets Colorectal Cancer Stem Cells 174
Validation of an LC-MS/MS Method for Urinary Lactulose and Mannitol Quantification: Results in Patients with Irritable Bowel Syndrome 174
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 172
Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn's disease: new prospective roles of CT enterography 172
Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report 171
Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn's disease: new prospective roles of CT enterography 168
Dysbiosis, gut microbiota modulation and intestinal permeability in recurrent cystitis patients and concomitant gastrointestinal pathologies 166
Use and indications of cholestyramine and bile acid sequestrants 165
Adverse Food Reactions in Inflammatory Bowel Disease: State of the Art and Future Perspectives 164
Dietary magnesium: the magic mineral that protects from colon cancer? 162
Dietary Magnesium Alleviates Experimental Murine Colitis Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel 162
Signs of dissociation and symptoms of post-traumatic stress disorder in inflammatory bowel disease. A case-control study 162
The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors 161
The gastrointestinal microbiome - functional interference between stomach and intestine 160
European consensus conference on faecal microbiota transplantation in clinical practice 159
Tumour necrosis factor-related apoptosis-inducing ligand (trail): a possible pathogenic role in chronic plaque psoriasis 159
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 159
Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review 156
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation 156
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 155
Origin of celiac disease: How old are predisposing haplotypes? 154
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 154
Tumor necrosis factor-α and solute carrier family 22 member 4 gene polymorphisms as potential determinants of intestinal dysbiosis 154
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 153
Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice 153
Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study 152
-Extraintestinal manifestations in inflammatory Bowel disease. 152
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 152
International consensus statement on microbiome testing in clinical practice 151
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 151
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 150
Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis 150
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome 150
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing. 150
Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial 149
Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials 148
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 148
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 147
The role of inflammatory bowel disease nurses for patients on biologic therapy during the COVID-19 pandemic 146
Differential CD133 expression pattern during mouse colon tumorigenesis 145
Bacillus clausii and gut homeostasis: state of the art and future perspectives 144
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 143
Sustainability of Endovenous Iron Deficiency Anaemia Treatment: Hospital-Based Health Technology Assessment in IBD Patients 143
Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease 143
Gut microbial flora, prebiotics and probiotics in IBD: their current usage and utility 142
Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors? 141
A novel pathogenic role for microvasculature in inflammatory bowel disease. 140
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 140
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 139
Use and indications of cholestyramine and bile acid sequestrants 138
Dietary magnesium alleviates experimental murine colitis through modulation of gut microbiota 138
Cost-effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy 138
An Integrative Multi-omic Analysis defines Gut Microbiota, Mycobiota and Metabolic fingerprints in Ulcerative Colitis Patients 137
Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. 136
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 136
Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools 133
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 133
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 133
Acute refractory intestinal pseudo-obstruction in MELAS: efficacy of prucalopride 132
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives 131
Addressing Nutritional Knowledge Gaps in Inflammatory Bowel Disease: A Scoping Review 130
Akkermansia muciniphila: key player in metabolic and gastrointestinal disorders 130
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 130
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 130
Commensal Clostridia: leading players in the maintenance of gut homeostasis 129
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility 129
Extracellular Vesicles: Novel Potential Therapeutic Agents in Inflammatory Bowel Diseases 128
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 128
A) Platelets: new players in the mucosal scenario of inflammatory bowel disease. 127
Mesenchymal Stem Cells Reduce Colitis in Mice via Release of TSG6, Independently of Their Localization to the Intestine 127
The current practice of lynch syndrome diagnosis and management in Italy: A qualitative assessment 127
Ecology and Machine Learning-Based Classification Models of Gut Microbiota and Inflammatory Markers May Evaluate the Effects of Probiotic Supplementation in Patients Recently Recovered from COVID-19 126
Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons 126
Prevention and treatment of venous thromboembolism in patients with IBD: a trail still climbing 126
Totale 17.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.744 120 83 37 101 123 57 26 241 86 190 345 335
2022/20233.959 513 511 297 601 238 467 195 343 455 80 161 98
2023/20242.401 105 537 99 153 100 317 186 94 127 135 264 284
2024/20255.261 103 152 431 155 431 200 313 207 635 589 1.114 931
2025/202614.419 1.922 526 939 1.864 2.459 738 2.211 735 1.003 994 505 523
2026/2027694 694 0 0 0 0 0 0 0 0 0 0 0
Totale 33.337